BriaCell CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June
June 09 2020 - 5:30AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, is pleased to announce that Dr. Bill Williams, BriaCell’s
President & CEO, has been invited to present at 3rd Annual
Next-Gen Immuno-Oncology Congress, a virtual event, will be held on
June 25 - 26, 2020.
Details of BriaCell’s oral presentation are the
following:
Event: 3rd Annual Next-Gen
Immuno-Oncology CongressDate: June 26,
2020Time: 9:30 Eastern TimeTitle:
Cancer Immunotherapy: A Targeted, Personalized and Off-the-Shelf
ApproachSession: Stream B, Immune Checkpoint
Inhibitors, Immune Modulating Agents & Tumor
Micro-Environment
Following the presentations, copies of the
presentations will be posted
on https://briacell.com/novel-technology/scientific-publications/.
About Next-Gen Immuno-Oncology Congress
The 3rd Annual Next-Gen Immuno-Oncology Congress
provides an opportunity for experts in the field to discuss the
latest in antibodies, cellular therapy and immune-checkpoint
research, learn of the new case studies of immuno-oncology projects
in development, and contribute to interactive Q&A sessions with
their peers to deliberate key topics of relevance, explore the
latest platforms and technologies on the market for development,
and discuss the best tools for their research in
immuno-oncology.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.comPhone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024